| Population 2015 |
101 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
14 |
(8.8–19) |
13 |
(8.7–19) |
| Mortality (HIV+TB only) |
0.44 |
(0.24–0.7) |
0.44 |
(0.24–0.7) |
| Incidence (includes HIV+TB) |
324 |
(279–373) |
322 |
(277–370) |
| Incidence (HIV+TB only) |
4.3 |
(3.3–5.4) |
4.3 |
(3.3–5.4) |
| Incidence (MDR/RR-TB)** |
17 |
(14–20) |
17 |
(14–20) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
14 |
(6.4–22) |
100 |
(64–135) |
114 |
(71–156) |
| Males |
17 |
(11–23) |
194 |
(152–236) |
211 |
(163–259) |
| Total |
31 |
(22–40) |
294 |
(266–322) |
324 |
(279–373) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
286 544 |
| Total new and relapse |
276 672 |
| - % tested with rapid diagnostics at time of diagnosis |
20% |
| - % with known HIV status |
13% |
| - % pulmonary |
97% |
| - % bacteriologically confirmed among pulmonary |
36% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
85% (74–99) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.04 (0.03–0.06) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
255 |
<1% |
| - on antiretroviral therapy |
178 |
70% |
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
15 000
(12 000–18 000) |
| Estimated % of TB cases with MDR/RR-TB |
2.6% (1.8–3.3) |
29% (21–38) |
|
| % notified tested for rifampicin resistance |
1% |
45% |
17 351 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
414 |
| Laboratory-confirmed cases |
MDR/RR-TB: 3 788, XDR-TB: 2 |
| Patients started on treatment **** |
MDR/RR-TB: 4 142, XDR-TB: 12 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
92% |
219 737 |
| Previously treated cases, excluding relapse, registered in 2014 |
83% |
6 062 |
| HIV-positive TB cases, all types, registered in 2014 |
52% |
174 |
| MDR/RR-TB cases started on second-line treatment in 2013 |
49% |
1 968 |
| XDR-TB cases started on second-line treatment in 2013 |
50% |
6 |
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
43% |
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
14% (13–16) |
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
104 |
| Funding source: 21% domestic, 41% international, 38% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |